Clinical Trial AdvancementsGritstone's GRANITE study shows promising early results, particularly for high-risk patients, signaling potential for positive impacts on progression-free survival and patient outcomes.
Financial StabilityThe company has a strong financial position, with enough cash to fund its operations well into the future, ensuring continued progress in its projects and stability for investors.
Regulatory MilestonesWith a potential end-of-Phase 2 meeting with the FDA on the horizon, Gritstone is poised for critical regulatory advancements that could significantly boost investor confidence.